Figures & data
Table 1. Summarized results from common direct costs outcomes reported in studies by Bolge et al. [Citation52,Citation64,Citation65].a
Table 2. Summarized results from common indirect cost outcomes reported in studies by Bolge et al. [Citation52,Citation64,Citation65].a
Figure 2. QoL (mean MCS and PCS scores) of patients with insomnia compared to good sleepers and the impact of using sleep medication.
![Figure 2. QoL (mean MCS and PCS scores) of patients with insomnia compared to good sleepers and the impact of using sleep medication.](/cms/asset/be6286e6-6943-479a-9c10-7dd72ed4c42d/ines_a_1995383_f0002_c.jpg)
Figure 3. QoL of patients with comorbid insomnia and type 2 diabetes mellitus compared to those without insomnia.
![Figure 3. QoL of patients with comorbid insomnia and type 2 diabetes mellitus compared to those without insomnia.](/cms/asset/93966f48-95de-4439-8a7a-c90218619cd4/ines_a_1995383_f0003_c.jpg)
Figure 4. Geographic distribution of publications reporting data on off-label treatment of insomnia stratified by drug-class and region.
![Figure 4. Geographic distribution of publications reporting data on off-label treatment of insomnia stratified by drug-class and region.](/cms/asset/d39e6e40-61e0-495a-99a1-98fab48827bf/ines_a_1995383_f0004_c.jpg)
Supplemental Material
Download PDF (736.4 KB)Data availability statement
No new data were generated or analyzed in support of this research.